Development

Mvasi, Kanjinti Add Heft to Amgen's Third-Quarter Sales

October 29th 2020

By Tony Hagen

Amgen said its sales results for Mvasi (bevacizumab) and Kanjinti (trastuzumab) give it confidence that the US market for biosimilars is more viable than generally perceived.

Alvotech Locks In $65 Million for Biosimilar Development

October 27th 2020

By Tony Hagen

Article

With a sizeable round of fresh capital, Alvotech hopes to bring monoclonal antibodies and fusion proteins through the development pipeline.

Henlius Inks Global Bevacizumab Biosimilar Distribution Deal

October 21st 2020

By Tony Hagen

Article

Shanghai Henlius Biotech will share development and distribution of its bevacizumab biosimilar candidate HLX04 with Zhuhai Essex and Essex Bio-Investment.

NeuClone's Ustekinimab Candidate Shines in Phase 1 Trial

October 20th 2020

By Tony Hagen

Article

Demonstrated biosimilarity across clinical parameters puts this drug among NeuClone's leading product candidates.

CT-P10 and Reference Rituximab Evaluated in Primary Sjögren Syndrome

October 20th 2020

By Deana Ferreri, PhD

Article

Investigators note similar efficacy and safety profiles in real-life study of reference and biosimilar forms of rituximab.

ICER: Infliximab Is Highest in Cost-Effectiveness for UC

October 19th 2020

By Skylar Jeremias

Article

Reviewers found that costs of reference infliximab and its biosimilars make it the most cost-effective therapy for ulcerative colitis (UC) among targeted immune modulators.

Revance Reports Positive Findings for Potential Botox Competitor

October 15th 2020

By Tony Hagen

Article

DaxibotulinumtoxinA met all end points in a study demonstrating longer duration of action, safety, and tolerability.

Alexion, Celltrion Notch Product Development Gains

October 14th 2020

By Tony Hagen

Article

Alexion and Celltrion separately announce advances in their drug development and marketing efforts.

Interview: Understanding the Attraction for PD-1 Inhibitor Biosimilars

October 13th 2020

By Tony Hagen

Article

Years ahead of patent expirations for programmed death-1 (PD-1) inhibitors, biosimilar companies have begun focusing on these targeted drugs.

PIRG Files Amicus Brief in Support of Humira Plaintiffs

October 13th 2020

By Tony Hagen

Article

The US Public Interest Research Group (PIRG) contends AbbVie's patent thicket for Humira (adalimumab) will encourage anticompetitive practices by other manufacturers.